KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Research & Development (2019 - 2025)

Historic Research & Development for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $50.5 million.

  • Royalty Pharma's Research & Development rose 1000000.0% to $50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.0 million, marking a year-over-year increase of 2000000.0%. This contributed to the annual value of $2.0 million for FY2024, which is 9615.38% down from last year.
  • As of Q3 2025, Royalty Pharma's Research & Development stood at $50.5 million, which was up 1000000.0% from $300.5 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Research & Development peaked at $300.5 million during Q2 2025, and registered a low of $500000.0 during Q1 2023.
  • Moreover, its 5-year median value for Research & Development was $3.1 million (2021), whereas its average is $43.8 million.
  • As far as peak fluctuations go, Royalty Pharma's Research & Development plummeted by 9950.25% in 2023, and later surged by 6000000.0% in 2025.
  • Over the past 5 years, Royalty Pharma's Research & Development (Quarter) stood at $103.8 million in 2021, then crashed by 51.35% to $50.5 million in 2022, then tumbled by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then soared by 10000.0% to $50.5 million in 2025.
  • Its Research & Development stands at $50.5 million for Q3 2025, versus $300.5 million for Q2 2025 and $50.5 million for Q1 2025.